Aclaris Therapeutics (8AT) Stock Statistics & Valuation Metrics
Total Valuation
Aclaris Therapeutics has a market cap or net worth of EUR 521.50M. The enterprise value is EUR 665.37M.
- Market Cap
- EUR 521.50M
- Enterprise Value
- EUR 665.37M
Share Statistics
Aclaris Therapeutics has 147,198,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 147,198,900
- Owned by Insiders
- 11.77%
- Owned by Institutions
- 1.18%
Financial Efficiency
Aclaris Therapeutics’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -57.70%.
- Return on Equity (ROE)
- -0.63
- Return on Assets (ROA)
- -0.40
- Return on Invested Capital (ROIC)
- -57.70%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 110.23K
- Profits Per Employee
- -914.41K
- Employee Count
- 71
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Aclaris Therapeutics is -6.84. Aclaris Therapeutics’s PEG ratio is -0.15.
- PE Ratio
- -6.84
- PS Ratio
- 71.10
- PB Ratio
- 4.55
- Price to FCF
- -9.40
- Price to Operating Cash Flow
- -9.13
- PEG Ratio
- -0.15
Income Statement
In the last 12 months, Aclaris Therapeutics had revenue of 7.83M and earned -64.92M in profits. Earnings per share was -0.53.
- Revenue
- 7.83M
- Gross Profit
- 5.74M
- Operating Income
- -76.38M
- Pretax Income
- -64.92M
- Net Income
- -64.92M
- EBITDA
- -64.47M
- Earnings Per Share (EPS)
- -0.53
Cash Flow
In the last 12 months, operating cash flow was -62.06M and capital expenditures -118,000, giving a free cash flow of -62.18M billion.
- Operating Cash Flow
- -62.06M
- Free Cash Flow
- -62.18M
- Free Cash Flow per Share
- -0.44
Dividends & Yields
Aclaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.64%
- Earnings Yield
- -13.37%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- 74.29%
- 50-Day Moving Average
- 4.34
- 200-Day Moving Average
- 3.91
- Relative Strength Index (RSI)
- 44.82
- Average Volume (3m)
- 592
Important Dates
Aclaris Therapeutics upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Aclaris Therapeutics as a current ratio of 5.28, with Debt / Equity ratio of 2.05%
- Current Ratio
- 5.28
- Quick Ratio
- 5.28
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.28
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Aclaris Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Aclaris Therapeutics EV to EBITDA ratio is -7.50, with an EV/FCF ratio of -9.09.
- EV to Sales
- 68.77
- EV to EBITDA
- -7.50
- EV to Free Cash Flow
- -9.09
- EV to Operating Cash Flow
- -9.11
Balance Sheet
Aclaris Therapeutics has EUR 91.56M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 91.56M billion.
- Cash & Marketable Securities
- EUR 91.56M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 91.56M
- Net Cash Per Share
- EUR 0.62
- Tangible Book Value Per Share
- EUR 0.87
Margins
Gross margin is 95.61%, with operating margin of -1050.16%, and net profit margin of -921.50%.
- Gross Margin
- 95.61%
- Operating Margin
- -1050.16%
- Pretax Margin
- -921.50%
- Net Profit Margin
- -921.50%
- EBITDA Margin
- -916.38%
- EBIT Margin
- -921.50%
Analyst Forecast
The average price target for Aclaris Therapeutics is EUR 10.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 10.71
- Price Target Upside
- 211.10% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- -54.68%
- EPS Growth Forecast
- 60.64%
Scores
- Smart Score
- 10
- AI Score
- ―